Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
Authors' conclusion
This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab and starting biologics earlier in the disease course.
Study context
- Population
- Children and young people with JIA starting biologics between 1 January 2010 and 7 September 2021 in the UK JIA Biologics Registermedian follow-up 2.7 years
- Participants
- 1,451 children
- Outcome
- Stopping biologics for physician-reported remission; re-starting biologics and time to re-start; factors associated with re-starting
Methodological detailsUK JIA Biologics Register, multiple imputation for missing data
- UK JIA Biologics Register
- Multiple imputation for missing data
Main finding
As reported in the abstract
Stopped biologics for remission, after a median of 2.2 years (IQR 1.7, 3.0)
269
19%
Later re-started therapy (of those with follow-up data, N = 220), after a median of 4.7 months
118
54%
Re-starting the same biologic
84%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Factors associated with re-starting biologicsAny-line tocilizumab (prior to stopping)vs Etanercept | 0.3 (0.2–0.7) | |
| Factors associated with re-starting biologicsLonger disease duration prior to biologics · per year increase | 1.1 (1.0–1.2) | |
| 0.20.5125Odds ratio (log scale) |
Factors associated with re-starting biologics
| OR (95% CI) | ||
|---|---|---|
| Prior uveitis | 2.5 (1.3–4.9) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). Published 15 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →